Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107593338 | 10759333 | 8 | F | 20140422 | 20160809 | 20150203 | 20160815 | EXP | PHHY2014CA050035 | NOVARTIS | 54.94 | YR | F | Y | 0.00000 | 20160815 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107593338 | 10759333 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | ONCE/SINGLE (TEST DOSE) | 19667 | 1X | |||||||||
| 107593338 | 10759333 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (EVERY 4 WEEKS) | 0 | 30 | MG | /month | |||||||
| 107593338 | 10759333 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (EVERY 4 WEEKS) | 0 | 40 | MG | /month | |||||||
| 107593338 | 10759333 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, TIW EVERY 3 WEEKS | 0 | 40 | MG | Q3W | |||||||
| 107593338 | 10759333 | 5 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, TIW EVERY 3 WEEKS | 0 | 60 | MG | Q3W | |||||||
| 107593338 | 10759333 | 6 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (EVERY 4 WEEKS) | 0 | 60 | MG | /month | |||||||
| 107593338 | 10759333 | 7 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, TIW EVERY 3 WEEKS | 0 | 60 | MG | Q3W | |||||||
| 107593338 | 10759333 | 8 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (EVERY 4 WEEKS) | 0 | 60 | MG | /month | |||||||
| 107593338 | 10759333 | 9 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, TIW (EVERY 3 WEEKS) | 0 | 60 | MG | Q3W | |||||||
| 107593338 | 10759333 | 10 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 107593338 | 10759333 | 1 | Pancreatic neuroendocrine tumour |
| 107593338 | 10759333 | 2 | Pancreatic neuroendocrine tumour |
| 107593338 | 10759333 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 107593338 | 10759333 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 107593338 | 10759333 | Blood pressure increased | |
| 107593338 | 10759333 | Blood pressure systolic increased | |
| 107593338 | 10759333 | Diarrhoea | |
| 107593338 | 10759333 | Fall | |
| 107593338 | 10759333 | Fatigue | |
| 107593338 | 10759333 | Flushing | |
| 107593338 | 10759333 | Heart rate decreased | |
| 107593338 | 10759333 | Inappropriate schedule of drug administration | |
| 107593338 | 10759333 | Oropharyngeal pain | |
| 107593338 | 10759333 | Pyrexia | |
| 107593338 | 10759333 | Wrist fracture |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 107593338 | 10759333 | 1 | 20140213 | 20140213 | 0 | |
| 107593338 | 10759333 | 2 | 20140221 | 0 | ||
| 107593338 | 10759333 | 5 | 20151120 | 0 |